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Autism spectrum disorders (ASD) are etiologically heterogeneous, with hundreds of rare, highly penetrant
mutations and genomic imbalances involved, each contributing to a very small fraction of cases. In this issue of
Molecular Autism, Soorya and colleagues evaluated 32 patients with Phelan-McDermid syndrome, caused by either
deletion of 22q13.33 or SHANK3 mutations, using gold-standard diagnostic assessments and showed that 84% met
criteria for ASD, including 75% meeting criteria for autism. This study and prior studies demonstrate that this
syndrome appears to be one of the more penetrant causes of ASD. In this companion review, we show that in
samples ascertained for ASD, SHANK3 haploinsufficiency is one of the more prevalent monogenic causes of ASD,
explaining at least 0.5% of cases. We note that SHANK3 haploinsufficiency remains underdiagnosed in ASD and
developmental delay, although with the increasingly widespread use of chromosomal microarray analysis and
targeted sequencing of SHANK3, the number of cases is bound to rise.Autism spectrum disorders (ASD) are highly genetic dis-
orders, and current estimates indicate that there could
be over 1,000 genes that contribute to ASD risk [1]. Very
few genes are therefore likely to contribute to more than
1% of ASD, and mutations of FMR1 (the gene disrupted
in Fragile X syndrome) and MECP2 (the gene disrupted
in Rett syndrome), considered among the most common
causes of ASD, explain 2% and 0.5% of ASD, respectively.
Here we show that loss of a functional copy of SHANK3
is among the more prevalent rare causes of ASD.
SHANK3 codes for a scaffolding protein that lies at the
core of the postsynaptic density in glutamatergic synapses.
22q13.3 deletions and mutations that lead to a loss of a
functional copy of SHANK3 cause Phelan-McDermid syn-
drome, characterized by moderate to profound intellectual
disability, severely delayed or absent speech, hypotonia,
and ASD or ASD traits [2,3]. Dysmorphic features are
usually mild and include dysplastic nails, large or promin-
ent ears, long eyelashes, wide nasal bridge, bulbous nose
and sacral dimple. Decreased perspiration, mouthing or
chewing non-food items, and decreased perception of pain* Correspondence: Catalina.Betancur@inserm.fr
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distribution, and reproduction in any mediumare frequently noted. Other features include seizures, brain,
renal and cardiac malformations, motor deficits, gastro-
esophageal reflux, lymphedema, and immune defects. Be-
cause of its nonspecific clinical presentation, the diagnosis
requires molecular genetic testing to identify SHANK3
deletions (the preferred method being chromosome micro-
array analysis) or mutations.
In this issue, Soorya and colleagues evaluated ASD in
a sample of 32 patients with SHANK3 haploinsufficiency
using standard diagnostic tests — the Autism Diagnostic
Interview-Revised and the Autism Diagnostic Observation
Schedule — and showed that 84% (27/32) met criteria for
ASD, including 75% (24/32) meeting criteria for autism.
These findings indicate that Phelan-McDermid syndrome
is one of the more highly penetrant causes of autism [4].
We can get a reasonably accurate estimate of the fre-
quency of SHANK3 deletions and mutations in ASD
through the review of recent studies in ASD that made
use of either chromosome microarray or targeted re-
sequencing of SHANK3. A survey of all relevant studies,
including negative studies, indicates that at least 0.5% of
subjects with ASD have haploinsufficiency at the SHANK3
locus. Table 1 shows 14 genome-wide microrray studies
in ASD that would reliably detect larger dosage imbalanceed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 22q13.3 deletions involving SHANK3 identified




Sebat et al. [5] 165 1 de novo
Moessner et al. [6] 400 2 de novo a
Weiss et al. [7] 299 b 0
van der Zwaag et al. [8] 105 0
Guilmatre et al. [9] 260 2 de novo
Qiao et al. [10] 100 0
Schaefer et al. [11] 68 0
Pinto et al. [12] + Autism Genome Project
(manuscript in preparation)
2,446 3 de novo c
Shen et al. [13] 848 0
Rosenfeld et al. [14] 1,461 4 (2 de novo,
2 unknown)
Bremer et al. [15] 223 1 de novo
Sanders et al. [16] 1,124 0
Wisniowiecka-Kowalnik et al. [17] 145 0
Girirajan et al. [18] 243 0
Total 7,887 13 (0.16%)
a Family 3524, with two affected siblings with an apparent de novo SHANK3
deletion, was part of another cohort and was thus not included here. In
addition, this family’s deletion was previously reported in Sebat et al. [5].
b 299 patients from deCODE (Iceland); subjects from AGRE and Boston
Children’s Hospital overlap other studies and were not included here.
c One family (2072) was already reported in Sebat et al. [5] (89-3524-100) and
Moessner et al. [6] (3524), and was not included here.
Figure 1 De novo SHANK3mutations identified through large-scale
surveys in autism spectrum disorders. See Table 2 for references.
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viduals, and collectively identified 13 deletions (0.16%).
This frequency is likely underestimated because, in many
of these studies, efforts were made at the recruiting sites
to exclude cases with severe intellectual disability or syn-
dromic autism (that is, those with dysmorphic features or
other congenital anomalies). In addition, many of the pa-
tient samples had been prescreened for cytogenetic abnor-
malities and microdeletion/microduplication syndromes.
Furthermore, although we tried to exclude studies that
had clearly overlapping samples, there are probable sam-
ple overlaps among the remaining studies (overlappingTable 2 De novo SHANK3 mutations identified through large-
Study Subjects Mutations Nucleo
Durand et al. [2] 227 1 g.5115
Moessner et al. [6] 400 1 g.5112
Gauthier et al. [22] 427 1 g.5115
Schaaf et al. [23] 339 0
Boccuto et al. [24] 221 2 g.5111
g.5116
Total 1,614 5 (0.31%)
a Genomic locations are based on GRCh37 (hg 19). b SHANK3 reference sequence NASD cases without a deletion would lead to apparently de-
creased rates of the deletion). Moreover, because Phelan-
McDermid syndrome is a mostly sporadic disorder (the
deletion is de novo in 80% of cases, while in 20% it results
from familial balanced translocations or other chromo-
some rearrangements), screening ASD samples with an
overrepresentation of multiplex families will necessarily
result in a lower yield. Finally, it should be noted that
most of the microarray analyses reviewed here would
have missed small deletions involving only SHANK3.
There have been five studies in ASD that have exam-
ined SHANK3 for mutations, using targeted resequencing
(Table 2 and Figure 1). These studies identified five de
novo deleterious mutations in 1,614 subjects with ASD
(0.31%). The combined rate of deletions and mutations
in ASD is therefore 0.5%, making haploinsufficiency at
the SHANK3 locus one of the more common monogenic
causes of ASD. Studies in intellectual disability and develop-
mental delay confirm this rate of SHANK3 haploinsufficiency
in these disorders as well [19-21].
In conclusion, recent studies of patients with ASD in-
dicate that SHANK3 haploinsufficiency is found in ap-
proximately 0.5% of individuals with ASD. In addition,
Soorya and colleagues and prior publications indicate
that a very high proportion of individuals with SHANK3
haploinsufficiency have ASD.
Chromosome microarray analysis is still not routinely
carried out for individuals with unexplained developmen-
tal delay or ASD, in spite of recommendations from
several expert societies. In addition, SHANK3 is one of the
most GC-rich genes in the genome, and targeted re-
sequencing requires considerable optimization to reliably
sequence this gene. As a result, few clinical laboratoriesscale screening of autism spectrum disorder samples
tidea Proteinb Exon/intron
9940-51159941insG p.A1227fs exon 21
1844A>G p.Q321R exon 8
3476delG (splice site deletion) intron 19
7094C>G p.P141A exon 4
0144delG p.E1295fs exon 21
M_033517.1 (mRNA) and NP_277052.1 (protein).
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sequencing does a very poor job of adequately covering
SHANK3 because of the GC content. Thus, both clinical
and research studies will need to continue to use chromo-
some microarray analyses and Sanger methods to query
this important gene, until better whole-exome or whole-
genome sequencing protocols are developed. For all these
reasons, Phelan-McDermid syndrome remains undiag-
nosed in many individuals, denying them and their
families any benefits that derive from an etiological diag-
nosis. As Phelan-McDermid syndrome continues to be
studied we will understand more about this disorder,
including natural history and therapies that are most
beneficial for this group of individuals.
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